AB Science’s Masitinib/Docetaxel Benefits In Advanced Prostate Cancer
Improves PFS In Preselected Subgroup
Executive Summary
AB Science’s top-line results from a Phase III study suggest its lead candidate masitinib may be of benefit when combined with docetaxel chemotherapy in patients with early metastatic castration-resistant prostate cancer.